Liquidia Co. (NASDAQ:LQDA) CEO Roger Jeffs Sells 14,130 Shares of Stock

Liquidia Co. (NASDAQ:LQDA) CEO Roger Jeffs sold 14,130 shares of the firm’s stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $191,744.10. Following the completion of the transaction, the chief executive officer now directly owns 1,006,420 shares in the company, valued at $13,657,119.40. This represents a 1.38 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Liquidia Stock Up 0.6 %

Shares of Liquidia stock opened at $13.68 on Thursday. The company has a market cap of $1.17 billion, a P/E ratio of -8.39 and a beta of 0.23. The firm’s 50 day moving average price is $14.75 and its 200-day moving average price is $12.73. Liquidia Co. has a 52-week low of $8.26 and a 52-week high of $16.81.

Liquidia (NASDAQ:LQDA) last issued its quarterly earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.08). The business had revenue of $2.92 million for the quarter, compared to analyst estimates of $4.60 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. As a group, equities research analysts forecast that Liquidia Co. will post -1.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on LQDA. Scotiabank reaffirmed an “outperform” rating on shares of Liquidia in a research note on Thursday, March 20th. HC Wainwright reiterated a “buy” rating and issued a $29.00 target price on shares of Liquidia in a report on Thursday, March 20th. Needham & Company LLC restated a “buy” rating and issued a $25.00 price objective on shares of Liquidia in a report on Thursday, April 10th. Finally, Wells Fargo & Company began coverage on shares of Liquidia in a report on Friday, December 20th. They set an “overweight” rating and a $20.00 target price on the stock. One investment analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $26.63.

Institutional Investors Weigh In On Liquidia

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LQDA. GAMMA Investing LLC increased its holdings in shares of Liquidia by 65.6% during the first quarter. GAMMA Investing LLC now owns 2,961 shares of the company’s stock valued at $44,000 after acquiring an additional 1,173 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in Liquidia during the 4th quarter worth approximately $59,000. Summit Investment Advisors Inc. raised its holdings in shares of Liquidia by 35.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock worth $78,000 after buying an additional 1,719 shares during the last quarter. D. E. Shaw & Co. Inc. acquired a new stake in shares of Liquidia during the fourth quarter worth $142,000. Finally, EntryPoint Capital LLC acquired a new stake in shares of Liquidia during the fourth quarter worth $154,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).